Amarin Stock Forecast
NASDAQ: AMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
AMRN analyst consensus
Consensus (2 analysts)
none
Avg. price target
$12.50+4.25%
- Strong buy 0
- Buy 0
- Hold 0
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 2 Wall Street analysts covering Amarin (2026-10-08), 0 rate the stock a buy or strong buy, 0 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $12.50, with a high estimate of $13.00 and a low estimate of $12.00. The average target implies upside of 4.3% from the current price of $11.99.
The spread between the highest and lowest targets is 8.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AMRN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 0 | 0% |
| Hold | 0 | 0% |
| Sell | 1 | 50% |
| Strong sell | 1 | 50% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $12.00 | +0.08% |
| Average target | $12.50 | +4.25% |
| High target | $13.00 | +8.42% |